Clinical trials: Livedo Vasculitis
Raynaud's Phenomenon, Skin Necrosis
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.
- Trial name
- Anti-Vasospasm (NCT01378845)
- Testing
- Tracleer, Prostavasin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Christoph Hehrlein
Raynaud's Syndrome
Botulinum Toxin in the Treatment of Raynaud's
The investigators are studying a medical condition known as Raynaud's Phenomenon (RP). RP is a painful condition in which cold surroundings or stressful events trigger pain, a cold sensation, and in severe cases, sores and ulcers…
- Trial name
- NCT01233999
- Testing
- botulinum toxin A
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Raynaud Disease, Systemic Sclerosis
Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
This study evaluates the efficacy and safety of routine medical treatments of digital ulcers in patients with systemic sclerosis in a prospective cohort study.
- Conditions
- Raynaud Disease, Systemic Sclerosis, Digital Ulcer
- Trial name
- NCT02642146
- Testing
- Calcium Channel Blockers, Phosphodiesterase Inhibitors, Endothelin receptor blocker
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Seoul National University Hospital
Raynaud Disease, Scleroderma, Systemic
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
The aim of the study is to determine if postocclusive hyperemia of palmar and dorsal face of the hand with Laser speckle contrast imaging discriminate between patients with systemic sclerosis, subjects with primary Raynaud's…
- Trial name
- SPECIES (NCT01743612)
- Testing
- laser speckle contrast imaging, Cooling
- Where
- 2 sites in France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud Phenomenon
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
The prevalence of Raynaud phenomenon (RP), a reversible vaso-constriction with skin discoloration, is 5-10% in general population.
- Trial name
- NCT01280266
- Testing
- Udenafil or Amlodipine
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Seoul National University Hospital
Raynaud's Disease
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients…
- Trial name
- NCT00266669
- Testing
- Topical organogel with nitroglycerin
- Where
- 19 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Raynaud Phenomenon
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous…
- Conditions
- Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma
- Trial name
- RHEACT (NCT05204784)
- Testing
- Rheopheresis treatment, Intravenous Infusion
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Peter Korsten
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Scleroderma, Systemic Sclerosis
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand…
- Conditions
- Scleroderma, Systemic Sclerosis, Raynaud Phenomena, Raynaud's Disease
- Trial name
- STAR (NCT02396238)
- Testing
- Celution Device
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Cytori Therapeutics
Raynaud Disease
Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.
- Trial name
- NCT00251238
- Testing
- Ginkgo biloba extract EGb 761
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- VSM Geneesmiddelen b.v.
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for…
- Trial name
- NCT04915950
- Testing
- Temanogrel
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pfizer
Raynaud Disease
Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Patients with Raynaud's phenomenon suffer from painful attacks triggered by stress or cold causing acute lowering of blood flow through the digits.
- Trial name
- DIGIT (NCT01926847)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Raynaud Syndrome
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.
- Trial name
- NCT01291199
- Testing
- vardenafil
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- University of Cologne
Raynaud's Phenomenon, Digital Ulcers
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity and adversely affects the quality of life.
- Conditions
- Raynaud's Phenomenon, Digital Ulcers, Scleroderma
- Trial name
- NCT01117298
- Testing
- Tadalafil
- Where
- 4 sites in India
- Volunteers
- 66 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease
Metabolomic Analysis of Systemic Sclerosis
Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.
- Conditions
- Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease, Raynaud Disease, Vascular Disease
- Trial name
- SCLEROMICS (NCT02298777)
- Testing
- - Skin biopsy - Urine sample - Blood sample
- Where
- 4 sites in France
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Raynaud Phenomenon
Botulinum Toxin in Raynaud's Phenomenon
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe.
- Trial name
- NCT05125029
- Testing
- Botulinum toxin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Raynaud Phenomenon
Dermoscopy in Primary Raynaud's Phenomenon
Raynaud's phenomenon (RP) is very frequent in general population (up to 10%). Nailfold capillaroscopy (NFC) is recommended for patients presenting RP, to eliminate systemic disease such as systemic sclerosis.
- Trial name
- VASCUL-R (NCT04644523)
- Testing
- Dermoscopy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Raynaud Phenomenon
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
- Trial name
- NCT03639766
- Testing
- AbobotulinumtoxinA, Saline solution
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Skin Cancer, Skin Diseases
Multi-modal Quantitative Imaging of the Skin
This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.
- Conditions
- Skin Cancer, Skin Diseases, Atopic Dermatitis, Psoriasis
- Trial name
- DermaFlow (NCT06989216)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health